Given the originality displayed in the article, the high-quality research design, and the potential clinical impact, particularly in elucidating the effectiveness and safety of oral semaglutide for patients with metabolic dysfunction-associated steatotic liver disease (MASLD).

I believe this paper should be considered for expedited publication.

This study has certain innovativeness and clinical significance. It explores the efficacy and safety of oral semaglutide in patients with metabolic dysfunction-associated steatotic liver disease (MASLD) combined with type 2 diabetes mellitus (T2DM), providing new evidence for the treatment of this disease. The research method is relatively reasonable, the data is reliable, and the results show that oral semaglutide has a significant effect in improving the weight, blood glucose, blood lipids, liver enzymes, liver fibrosis markers, etc. of patients, and has good safety.